Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

239 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Continuous Infusion of Cilengitide Plus Chemoradiotherapy for Patients With Stage III Non-Small-cell Lung Cancer: A Phase I Study.
Massabeau C, Khalifa J, Filleron T, Modesto A, Bigay-Gamé L, Plat G, Dierickx L, Aziza R, Rouquette I, Gomez-Roca C, Mounier M, Delord JP, Toulas C, Olivier P, Chatelut E, Mazières J, Cohen-Jonathan Moyal E. Massabeau C, et al. Among authors: chatelut e. Clin Lung Cancer. 2018 May;19(3):e277-e285. doi: 10.1016/j.cllc.2017.11.002. Epub 2017 Nov 21. Clin Lung Cancer. 2018. PMID: 29221762 Clinical Trial.
Wide variation in tissue, systemic, and drain fluid exposure after oxaliplatin-based HIPEC: results of the GUTOX study.
de Jong LAW, Elekonawo FMK, Lambert M, de Gooyer JM, Verheul HMW, Burger DM, de Wilt JHW, Chatelut E, Ter Heine R, de Reuver PR, Bremers AJA, van Erp NP. de Jong LAW, et al. Among authors: chatelut e. Cancer Chemother Pharmacol. 2020 Jul;86(1):141-150. doi: 10.1007/s00280-020-04107-y. Epub 2020 Jun 27. Cancer Chemother Pharmacol. 2020. PMID: 32594200 Free PMC article. Clinical Trial.
Correction to: Wide variation in tissue, systemic, and drain fluid exposure after oxaliplatin‑based HIPEC: results of the GUTOX study.
de Jong LAW, Elekonawo FMK, Lambert M, de Gooyer JM, Verheul HMW, Burger DM, de Wilt JHW, Chatelut E, Ter Heine R, de Reuver PR, Bremers AJA, van Erp NP. de Jong LAW, et al. Among authors: chatelut e. Cancer Chemother Pharmacol. 2022 Aug;90(2):189-190. doi: 10.1007/s00280-022-04450-2. Cancer Chemother Pharmacol. 2022. PMID: 35731259 Free PMC article. No abstract available.
Prospective validation of an equation based on plasma cystatin C for monitoring the glomerular filtration rate in children treated with cisplatin or ifosfamide for cancer.
Lambert M, Alonso M, Munzer C, Zimoch MC, Malard L, Gambart M, Castex MP, Martins C, Pasquet M, Chatelut E. Lambert M, et al. Among authors: chatelut e. Cancer Chemother Pharmacol. 2024 Apr;93(4):393-395. doi: 10.1007/s00280-023-04597-6. Epub 2023 Oct 3. Cancer Chemother Pharmacol. 2024. PMID: 37789166
Dose and time dependencies of 5-fluorouracil pharmacokinetics.
Terret C, Erdociain E, Guimbaud R, Boisdron-Celle M, McLeod HL, Féty-Deporte R, Lafont T, Gamelin E, Bugat R, Canal P, Chatelut E. Terret C, et al. Among authors: chatelut e. Clin Pharmacol Ther. 2000 Sep;68(3):270-9. doi: 10.1067/mcp.2000.109352. Clin Pharmacol Ther. 2000. PMID: 11014408 Clinical Trial.
239 results